全球去中心化臨床試驗成長機會

Global Decentralized Clinical Trials Growth Opportunities

出版日期: 2023年09月15日 | 出版商:

Frost & Sullivan | 英文 84 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

日益激烈的競爭推動了全球範圍內的 DCT 計劃，為基於合作夥伴關係的成長模式鋪平了道路

自COVID-19大流行以來，全球去中心化臨床試驗（DCT）市場持續快速成長。 2020年加速引入DCT的背景是，參與臨床試驗的臨床實驗臨床實驗、臨床實驗臨床實驗合作者和患者的流動受到限制，全球臨床實驗活動大幅停頓。為了確保病患安全和研發活動的連續性，大多數臨床試驗贊助者和委外研發機構(CRO) 正在使用直接資料收集來支援遠端醫療、遠端來源資料檢驗和感測器/行動技術。我們採用了數位工具，例如支援臨床實驗業務的解決方案。

世界各地的法規機構正在與 DTRA（去中心化試驗和研究聯盟）等現有聯盟一起，推出大規模實施 DCT 模式的計劃和指南，旨在提高 DCT 的認知。我們支持引入測試。

北美憑藉強大的 DCT 供應商、CRO 和製藥贊助商繼續引領 DCT 市場。然而，亞太地區正在成為一個重要的地區，由於其患者多樣性、未經治療的人群和顯著的成本優勢，全球幾家主要的 CRO 都建立了牢固的立足點。此外，該地區越來越依賴遠端醫療和電子藥局解決方案，DCT 將在未來三到五年內變得更加普及。在世界其他地方，中東正準備擴大遠端試驗的使用，其中沙烏地阿拉伯和杜拜處於領先地位。包括 Oracle 和 AWS 在內的多家技術供應商均位於該地區，支援電子臨床解決方案的部署並推動成長。然而，與其他地區相比，該市場目前的成長相對緩慢。

始終需要透過適合用途的雲端基礎的平台解決方案來支援分散的臨床試驗。因此，CRO正在透過與技術供應商合作來建立分散式測試能力。此外，針對患者的線上培訓模組以及使用設備、聊天機器人和感測器進行家庭測試監控的安全技術正在支援大流行後採用分散式測試。

為因殘疾或地點而受到限制的患者提供居家醫療服務可以促進臨床試驗的持續。與受過攜帶式設備使用培訓的護理人員支援的居家醫療服務提供者合作，有助於 DCT 的順利實施。此外，CRO 正在探索多種管道，透過擴大 DCT 生態系統來創新試驗註冊和病人參與策略，包括倡導團體、社交媒體、使用線上醫生轉診系統以及部署人工智慧平台。我正在關注這一點。

The global decentralized clinical trial (DCT) market has been witnessing a continued surge after the COVID-19 pandemic. The accelerated DCT adoption in 2020 was driven by restricted mobility of site investigators, clinical research associates, and patients to participate in trials, which resulted in a significant halt in trial activities worldwide. To ensure patient safety and continuity in the R&D activities, most sponsors and contract research organizations (CROs) adopted digital tools to support trial operations, including telemedicine, remote source data verification, and sensor/mobile technology-enabled direct data-capture solutions.

Regulatory agencies around the world are coming up with initiatives and guidelines for large-scale adoption of DCT modalities, alongside existing alliances, such as Decentralized Trials & Research Alliance (DTRA), that work toward increasing DCT awareness, propelling remote trial uptake.

North America continues to lead the DCT market owing to a strong presence of DCT vendors, CROs, and pharma sponsors in the region, followed closely by Europe, which has abundant infrastructure for large-scale DCT uptake. Nevertheless, Asia-Pacific is emerging as a crucial region with several leading global CROs establishing strong bases due to patient diversity, treatment-naive population, and significant cost advantage. In addition, there is a growing reliance on telemedicine and ePharmacy solutions in the region, which will propel DCT uptake in 3 to 5 years. In the Rest of World region, the Middle East is gearing up for greater remote trial adoption, with Kingdom of Saudi Arabia and Dubai at the forefront. Several tech vendors, such as Oracle and AWS, have set up bases in the region to allow the uptake of eClinical solutions, promoting growth. However, at present, the market will have comparatively slower growth than other regions.

There will be a constant need to support decentralized trials through cloud-based platform solutions that are fit to purpose. Therefore, CROs are building decentralized trial capabilities by partnering with technology vendors. In addition, online training modules for patients and secure technology for at-home trial monitoring through devices, chatbots, and sensors have been driving the adoption of decentralized trials after the pandemic.

Home health services for patients with physical disabilities and restricted access due to location can promote retention in clinical trials. Partnering with home health service providers supported by nurses trained in portable equipment usage will facilitate smooth DCT implementation. In addition, CROs are focused on innovating trial enrollment and patient engagement strategies by exploring multiple channels, such as the use of advocacy groups, social media, and online physician referral systems, as well as implementing AI-enabled platforms, expanding the DCT ecosystem.

Strategic Imperatives

Why Is It Increasingly Difficult to Grow?
The Strategic Imperative 8™
The Impact of the Top 3 Strategic Imperatives on the Decentralized Clinical Trial (DCT) Industry
Growth Opportunities Fuel the Growth Pipeline Engine™

Growth Opportunity Analysis: Decentralized Clinical Trial Market

Scope of Analysis
Decentralized Clinical Trials Market Segmentation
Growth Metrics
Comparison of Traditional and Decentralized Clinical Trials
DCT Value Proposition: Achieving Patient Centricity
Decentralized Clinical Trials: Pharma Ecosystem
Decentralized Clinical Trials: Patient Ecosystem

Market Snapshot

Market Trend Analysis
Evolving DCT Landscape
Global DCT Initiatives and Guidelines
Implications of DCT Initiatives on the Global DCT Market
Implications of DCT Initiatives on Individual Stakeholders
Growth Drivers
Growth Restraints
DCT: Evolving Vendor Ecosystem

Business Model Trends

Business Model Trend: Global DCT Market
Partnership Trends Driving DCT Business Models
Strategic Partnerships in DCT Market

Expanding Capabilities with M&As and Platform/Product Launches

Key Mergers and Acquisitions
New Platform Launches

Growth Opportunity Analysis: Revenue Forecast Analysis, Global

Forecast Assumptions
Revenue Forecast: Global
Revenue Forecast Analysis
Revenue Forecast by Phases of Clinical Development
Revenue Percentage by Phase of Development
Revenue Forecast by Clinical Development Phases
Revenue Share Analysis by Therapy Areas
Revenue Share Analysis by Therapy Areas

Growth Opportunity Analysis: Revenue Forecast Analysis, By Regions

Revenue Forecast by Regions
Revenue Forecast Analysis by Region: DCT Market
Revenue Forecast Analysis: North America
Revenue Forecast Analysis: Europe
Revenue Forecast Analysis: Asia-Pacific (APAC)
Revenue Forecast Analysis: Rest of World (RoW)

Competitive Environment

Competitive Environment
Competitor Benchmarking: Pure-play DCT Vendors
Competitor Benchmarking: CROs (Enablers/DCT Vendors)
Competitor Benchmarking: DCT Enablers
Competitor Assessment

Growth Opportunity Universe

Growth Opportunity 1: Endpoint Assessment with Digital Biomarkers
Growth Opportunity 2: Digital Health Technology (DHT)-enabled Focus on Oncology Trials
Growth Opportunity 3: Adopting Partnership-based Approaches for Scaling DCT Capabilities